Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature
Marianna Meschiari(Azienda Ospedaliero-Universitaria di Modena), Cristina Mussini(University of Modena and Reggio Emilia), Iacopo Franconi(University of Pisa), Vincenzo Bianco, Gianluca Cuomo(Azienda Ospedaliero-Universitaria di Modena), Erica Bacca(University of Modena and Reggio Emilia), Andrea Bedini(Azienda Ospedaliero-Universitaria di Modena), Gabriella Orlando(University of Modena and Reggio Emilia)
Cited by 23
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|995
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
|CHEST Journal|2009|157
Migration and health: A retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy
|Journal of Infection and Public Health|2018|49
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study
|Open Forum Infectious Diseases|2024|33